Skip to main content
SpringerLink
Log in

Role of tobacco smoking in pharmacokinetics

  • Published:
Journal of Pharmacokinetics and Biopharmaceutics Aims and scope Submit manuscript

Abstract

The pervasiveness of tobacco use in our society and the frequency of altered disposition and pharmacological effects of many common therapeutic and recreational drugs in smokers make it apparent that the smoking habit should be considered as one of the primary sources of drug interactions in man. Most of the experimental work in man, animals, and tissue on enzyme systems indicates that the dominant effect of smoking is enhanced disposition caused by induction of hepatic microsomal enzymes. The primary causal agents are probably the polynuclear aromatic hydrocarbons, which are potent and persistent in tissues. While several of the hepatic microsomal drug-metabolizing enzymes are stimulated in smokers, the selectivity of this enhancement in activity is unpredictable and the effects of tobacco smoke on other potential rate-limiting disposition processes are largely unexplored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. World Health Organization Expert Committee on Smoking and Its Effects on Health. Smoking and disease: The evidence reveiwed.WHO Chron. 29:402–408 (1975).

    Google Scholar 

  2. S. S. Field. What smoking does to women.Reader's Digest, pp. 94–97, (January 1976).

  3. P. S. Larson and H. Silvette.Tobacco: Experimental and Clinical Studies: A Comprehensive Account of the World Literature, Williams and Wilkins, Baltimore, Suppl. I (1968), Suppl. II (1971), Suppl. III (1975).

    Google Scholar 

  4. National Clearinghouse for Smoking and Health.Bibliography on Smoking and Health, Center for Disease Control, Public Health Service, Department of Health, Education, and Welfare, Atlanta, Ga.

  5. A. H. Conney, E. J. Pantuck, K. C. Hsiao, R. Kuntzman, A. P. Alvares, and A. Kappas. Regulation of drug metabolism in man by environmental chemicals and diet.Fed. Proc. 36:1647–1652 (1977).

    CAS  PubMed  Google Scholar 

  6. H. Jick. Smoking and clinical drug effects.Med. Clin. N. Am. 58:1143–1149 (1974).

    CAS  PubMed  Google Scholar 

  7. P. S. Larson, H. B. Haag, and H. Silvette. Some effects of nicotine and smoking on metabolic functions.Clin. Pharmacol. Ther. 2:80–109 (1961).

    CAS  PubMed  Google Scholar 

  8. A. H. Beckett and E. J. Triggs. Enzyme induction in man caused by smoking.Nature 216:587 (1967).

    CAS  PubMed  Google Scholar 

  9. D. C. Wenzel and L. L. Broadie. Stimulatory effect of nicotine on the metabolism of meprobamate.Toxicol. Appl. Pharmacol. 8:455–459 (1966).

    CAS  PubMed  Google Scholar 

  10. I. Yamamoto, K. Nagai, H. Kimura, and K. Iwatsubo. Nicotine and some carcinogens in special reference to the hepatic drug-metabolizing enzymes.Jap. J. Pharmacol. 16:183–190 (1966).

    CAS  PubMed  Google Scholar 

  11. R. M. Welch, A. Loh, and A. H. Conney. Cigarette smoke: Stimulatory effect on metabolism of 3,4-benzpyrene by enzymes in rat lung.Life Sci. 10:215–221 (1971).

    CAS  Google Scholar 

  12. E. J. Pantuck, R. Kuntzman, and A. H. Conney. Decreased concentration of phenacetin in plasma of cigarette smokers.Science 175:1248–1250 (1972).

    CAS  PubMed  Google Scholar 

  13. E. J. Pantuck, K. -C. Hsiao, A. Maggio, K. Nakamura, R. Kuntzman, and A. H. Conney. Effect of cigarette smoking on phenacetin metabolism.Clin. Pharmacol. Ther. 15:9–17 (1973).

    Google Scholar 

  14. M. Gibaldi and D. Perier.Pharmacokinetics, Dekker, New York, 1975, pp. 243–250.

    Google Scholar 

  15. R. M. Welch, J. Cavallito, and A. Loh. Effect of exposure to cigarette smoke on the metabolism of benzo[a]pyrene and acetophenetidin by lung and intestine of rats.Toxicol. Appl. Pharmacol. 23:749–758 (1972).

    CAS  PubMed  Google Scholar 

  16. E. J. Pantuck, K. -C. Hsiao, S. A. Kaplan, R. Kuntzman, and A. H. Conney. Effects of enzyme induction on intestinal phenacetin metabolism in the rat.J. Pharmacol. Exp. Ther. 191:45–52 (1974).

    CAS  PubMed  Google Scholar 

  17. R. M. Welch, J. Cavallito, and D. D. Gillespie. Effect of analgesics and exposure to cigarette smoke on the metabolism of acetophenetidin by rat tissues.Drug Metab. Dispos. 1:211–215 (1973).

    CAS  PubMed  Google Scholar 

  18. R. M. Welch, C. R. Hughes, and R. L. DeAngelis. Effect of 3-methylcholanthrene pretreatment on the bioavailability of phenacetin in the rat.Drug Metab. Dispos. 4:402–406 (1976).

    CAS  PubMed  Google Scholar 

  19. R. E. Vestel, A. H. Norris, J. D. Tobin, B. H. Cohen, N. W. Shock, and R. Andres. Antipyrine metabolism in man: Influence of age, alcohol, caffeine, and smoking.Clin. Phamacol. Ther. 18:425–432 (1975).

    Google Scholar 

  20. J. T. Wilson, C. J. Van Boxtel, G. Alván, and F. Sjoqvist. Failure of vitamin C to affect the pharmacokinetic profile of antipyrine in man.J. Clin. Pharmacol. 16:265–270 (1976).

    CAS  PubMed  Google Scholar 

  21. P. Hart, G. C. Farrell, W. G. E. Cooksley, and L. W. Powell. Enhanced drug metabolism in cigarette smokers.Br. Med. J. 2:147–149 (1976).

    CAS  PubMed Central  PubMed  Google Scholar 

  22. R. M. Welch, R. L. DeAngelis, M. D. Wingfield, and T. W. Farmer. Elimination of antipyrine from saliva as a measure of metabolism in man.Clin. Pharmacol. Ther. 18:249–258 (1975).

    CAS  PubMed  Google Scholar 

  23. G. Kellermann and M. Luyten-Kellermann. Phenobarbital-induced drug metabolism in man.Toxicol. Appl. Pharmacol. 39:97–104 (1977).

    CAS  PubMed  Google Scholar 

  24. G. Kellermann, M. Luyten-Kellermann, M. G. Horning, and M. Stafford. Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone.Drug Metab. Dispos. 3:47–50 (1975).

    CAS  PubMed  Google Scholar 

  25. G. Kellermann, M. Luyton-Kellermann, M. G. Horning, and M. Stafford. Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes.Clin. Pharmacol. Ther. 20:72–80 (1976).

    CAS  PubMed  Google Scholar 

  26. G. C. Farrell, W. G. E. Cooksley, L. W. Powell, and P. Hart. Interaction between liver disease and chronic drug ingestion on hepatic drug metabolism. Submitted 1977.

  27. J. Kapitulnik, P. J. Poppers, and A. H. Conney. Comparative metabolism of benzo[a]pyrene and drugs in human liver.Clin. Pharmacol. Ther. 21:166–176 (1977).

    CAS  PubMed  Google Scholar 

  28. J. Jenne, H. Nagasawa, R. McHugh, F. MacDonald, and E. Wyse. Decreased theophylline half-life in cigarette smokers.Life Sci. 17:195–198 (1975).

    CAS  PubMed  Google Scholar 

  29. S. N. Hunt, W. J. Jusko, and A. M. Yurchak. Effect of smoking on theophylline disposition.Clin. Pharmacol. Ther. 19:546–551 (1976).

    CAS  PubMed  Google Scholar 

  30. J. R. Powell, J. -F. Thiercelin, S. Vozeh, L. Sansom, and S. Riegelman. The influence of cigarette smoking and sex on theophylline disposition.Am. Rev. Resp. Dis. 116:17–24 (1977).

    CAS  PubMed  Google Scholar 

  31. W. J. Jusko, J. J. Schentag, and J. R. Koup. Surveillance of factors affecting theophylline body clearances. Presented to the A.Ph. A. Academy of Pharmaceutical Sciences, New Orleans (1976).

  32. H. J. Pfeifer and D. J. Greenblatt. Decreased theophylline toxicity among cigarette smokers: A report from the Boston Collaborative Drug Surveillance Program.Chest 73 (1978), in press.

  33. S. M. Lohman and R. P. Miech. Theophylline metabolism by the rat liver microsomal system.J. Pharmacol. Exp. Ther. 196:213–225 (1976).

    Google Scholar 

  34. R. M. Welch, S. Y. Hsu, M. F. Kearney, and R. L. DeAngelis. Effect of aroclor 1254, phenobarbital and polycyclic aromatic hydrocarbons on the plasma clearance of caffeine in the rat.Clin. Phamacol. Ther. 22:791–798 (1977).

    CAS  Google Scholar 

  35. W. D. Parsons and A. Aldridge. Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene.Fed. Proc. 35:665 (1976).

    Google Scholar 

  36. J. M. Perel, M. J. Hurvic, and M. B. Kanzler. Pharmacodynamics of imipramine in depressed patients.Psychophamacol. Bull. 11:16–18 (1975).

    CAS  Google Scholar 

  37. J. M. Perel, M. Shostak, E. Gann, S. J. Kantor, and A. H. Glassman. Pharmacodynamics of imipramine and clinical outcome in depressed patients. In L. A. Gottschalk and S. Merlis (eds.),Pharmacokinetics of Psychoactive Drugs, Spectrum Publications, New York, 1976, pp. 229–241.

    Google Scholar 

  38. O. Pelletier. Bioavailability of synthetic and natural ascorbic acid.J. Am. Diet. Assoc. 64:271–275 (1974).

    CAS  PubMed  Google Scholar 

  39. O. Pelletier. Vitamin C and cigarette smokers.Ann. N.Y. Acad. Sci. 258:156–168 (1975).

    CAS  PubMed  Google Scholar 

  40. J. C. Linell, A. D. Smith, C. L. Smith, J. Wilson, and D. M. Mathews. Effects of smoking on metabolism and excretion of vitamin B12.Br. Med. J. 2:215–216 (1968).

    Google Scholar 

  41. G. Nymand. Maternal smoking and neonatal hyperbilirubinaemia.Lancet 2:173 (1974).

    CAS  PubMed  Google Scholar 

  42. A. H. Conney, R. Welch, R. Kuntzman, R. Chang, M. Jacobson, A. D. Munro-Faure, A. W. Peck, A. Bey, A. Poland, P. J. Poppers, M. Finster, and J. A. Wolff. Effects of environmental chemicals on the metabolism of drugs, carcinogens, and normal body constituents in man.Ann. N.Y. Acad. Sci. 179:155–172 (1971).

    CAS  PubMed  Google Scholar 

  43. S. W. Burney and L. Bonus. Cross-sectional assessment of laboratory variables in a healthy male population, cigarette smoking and laboratory values.Aging Human Dev. 3:89–94 (1972).

    Google Scholar 

  44. J. W. Crow, M. D. Pedrolain, F. Bodner, D. W. Shoeman, and D. L. Azarnoff. Glutethimide and 4-OH glutethimide: Pharmacokinetics and effect on human performance in smokers and nonsmokers.Clin. Pharmacol. Ther. 22:458–464 (1977).

    CAS  PubMed  Google Scholar 

  45. J. R. Bennett. Smoking and gastrointestinal tract.Gut 13:658–665 (1972).

    CAS  PubMed Central  PubMed  Google Scholar 

  46. A. H. Beckett, M. Rowland, and E. J. Triggs. Significance of smoking in investigation of urinary excretion rate of amines in man.Nature 207:200–201 (1965).

    CAS  PubMed  Google Scholar 

  47. U. Klotz, G. R. Avant, A. Hoyumpa, S. Schenker, and G. R. Wilkinson. The effects of age and liver disease on the disposition and elimination of diazepam in adult man.J. Clin. Invest. 55:347–359 (1975).

    CAS  PubMed Central  PubMed  Google Scholar 

  48. J. Q. Rose, S. A. Barron, and W. J. Jusko. Phenytoin disposition in smokers and nonsmokers. Presented at the A.Ph.A. Academy of Pharmaceutical Sciences Meeting, New York (1977).

  49. A. A. Mitchell. Smoking and warfarin dosage.New Engl. J. Med. 287:1153–1154 (1972).

    CAS  PubMed  Google Scholar 

  50. A. Yacobi, J. A. Udall, and G. Levy. Serum protein binding as a derminant of warfarin body clearance and anticoagulant effect.Clin. Pharmacol. Ther. 19:552–558 (1976).

    CAS  PubMed  Google Scholar 

  51. K. Bachmann and J. Tarloff. Influence of 3,4-benzo[a]pyrene pretreatment on warfarin hypoprothrombinemia and disposition in the rat.Toxicol. Appl. Pharmacol. 42:157–165 (1977).

    CAS  PubMed  Google Scholar 

  52. L. E. Mather, G. T. Tucker, A. E. Pflug, M. J. Lindop, and C. Wilkerson. Meperidine kinetics in man, intravenous injection in surgical patients and volunteers.Clin. Pharmacol. Ther. 17:21–30 (1975).

    CAS  PubMed  Google Scholar 

  53. T. R. Norman, G. D. Burrows, K. P. Maguire, G. Rubinstein, B. A. Scoggins, and B. Davies. Cigarette smoking and plasma nortriptyline levels.Clin. Pharmacol Ther. 21:453–456 (1977).

    CAS  PubMed  Google Scholar 

  54. R. E. Vestal, E. A. McGuire, J. D. Tobin, R. Andres, A. H. Norris, and E. Mezey. Aging and ethanol metabolism.Clin. Pharmacol. Ther. 21:343–354 (1977).

    CAS  PubMed  Google Scholar 

  55. R. R. Levine, E. W. Pelikan, and C. J. Kensler. The effect of cigarette smoking on the excretion of phenol red.Fed. Proc. 20:414 (1961).

    Google Scholar 

  56. D. P. Vaughan, A. H. Beckett, and D. S. Robbie. The influence of smoking on the inter-subject variation in pentazocine elimination.Br. J. Clin. Pharmacol. 3:279–283 (1976).

    CAS  PubMed Central  PubMed  Google Scholar 

  57. M. Keeri-Szanto and J. R. Pomeroy. Atmospheric pollution and pentazocine metabolism.Lancet 1:947–949 (1971).

    CAS  PubMed  Google Scholar 

  58. Boston Collaborative Drug Surveillance Program. Decreased clinical efficacy of propoxyphene in cigarette smokers.Clin. Pharmacol. Ther. 14:259–263 (1973).

    Google Scholar 

  59. C. Swett. Drowsiness due to chlorpromazine in relation to cigarette smoking.Arch. Gen. Psychiat. 31:211–213 (1974).

    PubMed  Google Scholar 

  60. Boston Collaborative Drug Surveillance Program. Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age.New Engl. J. Med. 288:277–280 (1973).

    Google Scholar 

  61. C. C. Seltzer, G. D. Friedman, A. B. Siegelaub, and M. F. Collen. Smoking habits and pain tolerance.Arch. Environ. Health 29:170–172 (1974).

    CAS  PubMed  Google Scholar 

  62. D. Ferguson. Smoking, drinking and non-narcotic analgesic habits in an occupational group.Med. J. Aust. 1:1271–1274 (1973).

    CAS  PubMed  Google Scholar 

  63. C. C. Seltzer, G. D. Friedman, and A. B. Siegelaub. Smoking and drug consumption in white, black, and oriental men and women.Am. J. Public Health 64:466–473 (1974).

    CAS  PubMed Central  PubMed  Google Scholar 

  64. H. I. Vapaatalo, P. J. Neuvonen, A. Tissari, R. Mansner, and M. K. Paasonen. Effect of cigarette smoking on diuresis induced by furosemide.Ann. Clin. Res. 3:159 (1971).

    CAS  PubMed  Google Scholar 

  65. A. Kershbaum, D. J. Pappajohn, and S. Bellet. Smoking effect on dexamethasone suppression test.Clin. Res. 17:287 (1969).

    Google Scholar 

  66. W. S. Frankl. The hemodynamic effects of propranolol hydrochloride after smoking.Am. J. Med. Sci. 250:623–628 (1967).

    Google Scholar 

  67. J. D. Coffman. Effect of propranolol on blood pressure and skin blood flow during cigarette smoking.J. Clin. Pharmacol. 9:39–44 (1969).

    CAS  Google Scholar 

  68. E. Zuskin. Interaction between effects of beta blockage and cigarette smoke on airways.J. Appl. Physiol. 36:449–452 (1974).

    CAS  PubMed  Google Scholar 

  69. M. Carruthers. Modification of the noradrenaline related effects of smoking by beta-blockade.Psychol. Med. 6:251–256 (1976).

    CAS  PubMed  Google Scholar 

  70. J. P. Conroy. Smoking and the anesthetic risk.Anesth. Analg. 48:388–400 (1969).

    CAS  PubMed  Google Scholar 

  71. K. H. Kilburn. Effects of tobacco smoke on biological systems.Scand. J. Resp. Dis. Suppl. 91:63–78 (1974).

    CAS  Google Scholar 

  72. J. N. Schumaker, C. R. Green, F. W. Best, and M. P. Newell. Smoke composition: An extensive investigation of water soluble portion of cigarette smoke.J. Agr. Food Chem. 25:310–320 (1977).

    Google Scholar 

  73. R. F. Severson, M. E. Snook, R. F. Arrendale, and O. T. Chortyk. Gas Chromatographic quantitation of polynuclear aromatic hydrocarbons in tobacco smoke.Anal. Chem. 48:1866–1872 (1976).

    CAS  PubMed  Google Scholar 

  74. A. McCormick, M. J. Nicholson, M. A. Baylis, and J. G. Underwood. Nitrosamines in cigarette smoke condensate.Nature 244:237–238 (1973).

    CAS  PubMed  Google Scholar 

  75. Y. H. Atallah, H. W. Dorough, and J. H. Thorstenson. Nature and fate of insecticide residues inhaled by rats in cigarette smoke.Drug Metab. Dispos. 3:513–519 (1975).

    CAS  PubMed  Google Scholar 

  76. T. Dalhamn, M. -L. Edfors, and R. Rylander. Retention of cigarette smoke components in human lungs.Arch. Environ. Health 17:746–748 (1968).

    CAS  PubMed  Google Scholar 

  77. R. I. Mitchell. Controlled measurement of smoke-particle retention in the respiratory tract.Am. Rev. Resp. Dis. 85:526–553 (1962).

    CAS  PubMed  Google Scholar 

  78. F. J. Akin, M. E. Snook, R. E. Severson, W. J. Chamberlain, and D. B. Walters. Identification of polynuclear aromatic hydrocarbons in cigarette smoke and their importance as tumorigens.J. Natl. Cancer Inst. 57:191–195 (1976).

    CAS  PubMed  Google Scholar 

  79. K. Bridbord, J. F. Finklea, J. K. Wagoner, J. B. Moran, and P. Caplan. Human exposure to polynuclear aromatic hydrocarbons. In R. I. Freudenthal and P. W. Jones (eds.),Carcinogenesis, Vol. 1:Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism, and Carcinogenesis, Raven Press, New York, 1976, pp. 319–324.

    Google Scholar 

  80. A. H. Conney. Pharmacologic implications of microsomal enzyme induction.Pharmacol. Rev. 19:317–366 (1967).

    CAS  PubMed  Google Scholar 

  81. D. V. Parke. Induction of the drug-metabolizing enzymes. In D. V. Parke (ed.),Enzyme Induction, Basic Life Sciences Series, Vol. 6, Plenum, London, 1975, pp. 207–271.

    Google Scholar 

  82. H. V. Gelboin. Mechanisms of induction of drug metabolism enzymes. In B. B. Brodie, J. R. Gillette, and H. S. Ackerman (eds.),Handbook of Experimental Pharmacology, Vol. 28 ofConcepts in Biochemical Pharmacology, Part 2, Springer-Verlag, Berlin, 1971, pp. 431–451.

    Google Scholar 

  83. C. D. Klaassen. Biliary flow after microsomal enzyme induction.J. Pharmacol. Exp. Ther. 168:218–223 (1969).

    CAS  PubMed  Google Scholar 

  84. C. D. Klaassen. Biliary excretion of drugs: Role of ligandin in newborn immaturity and in the action of microsomal enzyme inducers.J. Pharmacol. Exp. Ther. 195:311–319 (1975).

    CAS  PubMed  Google Scholar 

  85. A. S. Nies, G. R. Wilkinson, B. D. Rush, J. T. Strother, and D. G. McDevitt. Effects of alteration of hepatic microsomal enzyme activity on liver blood flow in the rat.Biochem. Pharmacol. 25:1991–1993 (1976).

    CAS  PubMed  Google Scholar 

  86. D. W. Nebert, J. Winker, and H. V. Gelboin. Aryl hydrocarbon hydroxyiase activity in human placenta from cigarette smoking and nonsmoking women.Cancer Res. 29:1763–1769 (1969).

    CAS  PubMed  Google Scholar 

  87. R. M. Welch, Y. E. Harrison, A. H. Conney, P. J. Poppers, and M. Finster. Cigarette smoking: Stimulatory effect on metabolism of 3,4-benzpyrene by enzymes in human placenta.Science 160:541–542 (1968).

    CAS  PubMed  Google Scholar 

  88. J. Kapitulnik, W. Levin, P. J. Poppers, J. E. Tomaszewski, D. M. Jerina, and A. H. Conney. Comparison of the hydroxylation of zoxazolamine and benzo[a]pyrene in human placenta: Effect of cigarette smoking.Clin. Pharmacol. Ther. 20:557–564 (1976).

    CAS  PubMed  Google Scholar 

  89. O. Pelkonen. Metabolism of benzo[a]pyrene in human adult and fetal tissues. In R. I. Freudenthal and P. W. Jones (eds.),Carcinogenesis, Vol. 1:Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism, and Carcinogenesis, Raven Press, New York, 1976, pp. 9–21.

    Google Scholar 

  90. P. Uotila and J. Marniemi. Variable effects of cigarette smoking on aryl hydrocarbon hydroxyiase, epoxide hydratase and UDP-glucuronosyltransferase activities in rat lung, kidney, and small intestinal mucosa.Biochem. Pharmacol. 25:2323–2328 (1976).

    CAS  PubMed  Google Scholar 

  91. J. B. Hook and W. R. Hewitt. Development of mechanisms for drug excretion.Am. J. Med. 62:497–506 (1977).

    CAS  PubMed  Google Scholar 

  92. A. P. Alvares, A. Kappas, W. Levin, and A. H. Conney. Inducibility of benzo[α]pyrene hydroxyiase in human skin by polycyclic hydrocarbons.Clin. Pharmacol. Ther. 14:30–40 (1973).

    CAS  PubMed  Google Scholar 

  93. G. Kellermann, C. R. Shaw, and M. Luyten-Kellermann. Aryl hydrocarbon hydroxyiase inducibility and bronchogenic carcinoma.New Engl. J. Med. 289:934–937 (1973).

    CAS  PubMed  Google Scholar 

  94. H. L. Gurtoo, N. Bejba, and J. Minowada. Properties, inducibility and an improved method of analysis of aryl hydrocarbon hydroxyiase in cultured human lymphocytes.Cancer Res. 35:1235–1243 (1975).

    CAS  PubMed  Google Scholar 

  95. B. Paigen, J. Minowada, H. L. Gurtoo, K. Paigen, N. B. Parker, E. Ward, N. T. Hayner, I. D. J. Bross, F. Bock, and R. Vincent. Distribution of aryl hydrocarbon hydroxyiase inducibility in cultured human lymphocytes.Cancer Res. 37:1829–1837 (1977).

    CAS  PubMed  Google Scholar 

  96. J. Ambre, D. Graeff, F. Bures, D. Haupt, and K. Deason. Antipyrine metabolism and bronchogenic carcinoma.J. Med. 8:57–70 (1977).

    CAS  PubMed  Google Scholar 

  97. C. Tschanz, C. E. Hignite, D. H. Huffman, and D. L. Azarnoff. Metabolic disposition of antipyrine in patients with lung cancer.Cancer Res. 37:3881–3886 (1977).

    CAS  PubMed  Google Scholar 

  98. W. J. Jusko. Bioavailability and disposition kinetics of phenytoin in man. In P. Kellaway and I. Peterson (eds.),Quantitative Analytic Studies in Epilepsy, Raven Press, New York, 1976, pp. 115–136.

    Google Scholar 

  99. G. P. Lewis, W. J. Jusko, L. L. Coughlin and S. Hartz. Cadmium accumulation in man: Influence of smoking, occupation, alcoholic habit and disease.J. Chron. Dis. 25:717–726 (1972).

    CAS  PubMed  Google Scholar 

  100. Federal Trade Commission.Tar and Nicotine Content of Cigarettes, Washington D.C., April 1976.

  101. P. F. Isaac and M. J. Rand. Cigarette smoking and plasma levels of nicotine.Nature 236:308–310 (1972).

    CAS  PubMed  Google Scholar 

  102. R. W. Ruddon and A. M. Cohen. Alteration of enzyme activity in rat liver following the acute and chronic administration of nicotine.Toxicol. Appl. Pharmacol. 16:613–625 (1970).

    CAS  PubMed  Google Scholar 

  103. R. P. Weber, J. M. Coon, and A. J. Triolo. Nicotine inhibition of the metabolism of 3,4-benzopyrene, a carcinogen in tobacco smoke.Science 184:1081–1083 (1974).

    CAS  PubMed  Google Scholar 

  104. A. H. Beckett, J. W. Gorrod, and P. Jenner. The effect of smoking on nicotine metabolismin vivo in man.J. Pharm. Pharmacol. Suppl. 23:62S-67S (1971).

    CAS  Google Scholar 

  105. L. H. Hawkins, P. V. Cole, and J. R. Harris. Smoking habits and blood carbon monoxide levels.Environ. Res. 11:310–318 (1976).

    CAS  PubMed  Google Scholar 

  106. L. H. Hawkins. Blood carbon monoxide levels as a function of daily cigarette consumption and physical activity.Br. J. Ind. Med. 33:123–125 (1976).

    CAS  PubMed Central  PubMed  Google Scholar 

  107. D. Rondia. Abaissement de l'activité de la benzopyrene hydroxylase hepatique in vivo apres Inhalation d'oxyde de carbone.Compt. Rend. Acad. Sci. 271:617–619 (1970).

    CAS  Google Scholar 

  108. D. M. Turner. The effects of some tobacco smoke constituents on foreign compound metabolism in the cat and the rat.Res. Commun. Chem. Pathol. Pharmacol. 16:425–442 (1977).

    CAS  PubMed  Google Scholar 

  109. M. R. Montgomery and R. J. Rubin. Oxygenation during inhibition of drug metabolism by carbon monoxide or hypoxic hypoxia.J. Appl. Physiol. 35:505–509 (1973).

    CAS  PubMed  Google Scholar 

  110. R. A. Roth and R. J. Rubin. Comparison of the effect of carbon monoxide and of hypoxic hypoxia. I.In vivo metabolism, distribution and action of hexobarbital.J. Pharmacol. Exp. Ther. 199:53–60 (1976).

    CAS  PubMed  Google Scholar 

  111. G. P. Lewis, L. L. Coughlin, W. J. Jusko, and S. Hartz. Contribution of cigarette smoking to cadmium accumulation.Lancet 1:291–292 (1972).

    CAS  PubMed  Google Scholar 

  112. R. E. Johnston, T. S. Miya, and R. C. Schnell. Cadmium potentiation of drug response-Role of the liver.Biochem. Pharmacol. 24:877–881 (1975).

    CAS  PubMed  Google Scholar 

  113. W. M. Hadley, T. S. Miya, and W. F. Bousquet. Cadmium inhibition of hepatic drug metabolism in the rat.Toxicol. Appl. Pharmacol. 28:284–291 (1974).

    CAS  PubMed  Google Scholar 

  114. D. D. Wagstaff. Stimulation of liver detoxication enzymes by dietary cadmium acetate.Bull. Environ. Contam. Toxicol. 10:328–332 (1973).

    CAS  PubMed  Google Scholar 

  115. E. S. Ferri and E. J. Baratta. Polonium 210 in tobacco, cigarette smoke, and selected human organs.Public Health Rep. 81:121–127 (1966).

    CAS  PubMed  Google Scholar 

  116. E. P. Radford and V. R. Hunt. Polonium 210: A volatile radioelement in cigarettes.Science 143:247–249 (1964).

    CAS  PubMed  Google Scholar 

  117. O. C. Becking. Trace elements and drug metabolism.Med. Gin. N. Am. 60:813–830 (1976).

    CAS  Google Scholar 

  118. P. W. Darby and J. Wilson. Cyanide, smoking, and tobacco amblyopia: Observations on the cyanide content of tobacco smoke.Br. J. Ophthalmol. 51:336–338 (1967).

    CAS  PubMed Central  PubMed  Google Scholar 

  119. A. R. Pettigrewand G. S. Fell. Simplified colorimetric determination of thiocyanate in biological fluids, and its application to investigation of the toxic amblyopias.Clin. Chem. 18:996–1000 (1972).

    CAS  PubMed  Google Scholar 

  120. D. Djuric, P. Raicevic, and I. Konstantinovic. Excretion of thiocyanates in the urine of smokers.Arch. Environ. Health 5:12–15 (1962).

    CAS  PubMed  Google Scholar 

  121. N. Oshino, Y. Imai, and R. Sato. Electron-transfer mechanism associated with fatty acid desaturation catalyzed by liver microsomes.Biochim. Biophys. Acta 128:13–28 (1966).

    CAS  PubMed  Google Scholar 

  122. T. Matsubara and Y. Tochino. Modification by cyanide of the aniline-binding reaction with cytochrome P-450.Arch. Biochem. Biophys. 172:696–705 (1976).

    CAS  PubMed  Google Scholar 

  123. H. W. Dorough. Cigarette smoke as a source of pesticide exposure.Bull. Environ. Contam. Toxicol. 13:101–107 (1975).

    CAS  PubMed  Google Scholar 

  124. R. K. Lee and S. A. Peoples. Cigarette smoking and its effects on the urinary DDA levels in man.Proc. W. Pharmacol. Soc. 16:240–243 (1973).

    CAS  Google Scholar 

  125. A. H. Conney, R. M. Welch, R. Kuntzman, and J. J. Burns. Effects of pesticides on drug and steroid metabolism.Clin. Pharmacol. Ther. 8:2–10 (1967).

    CAS  PubMed  Google Scholar 

  126. A. Kershbaum, D. J. Pappajohn, S. Bellet, M. Hirabayashi, and H. Shafiha. Effect of smoking and nicotine on adrenocortical secretion.J. Am. Med. Assoc. 203:275–278 (1968).

    CAS  Google Scholar 

  127. A. Kershbaum, H. Osada, D. J. Pappajohn, and S. Bellet. Effect of nicotine on the mobilization of free fatty acids from adipose tissuein vitro.Experientia 25:128 (1969).

    CAS  PubMed  Google Scholar 

  128. L. G. Dales, G. D. Friedman, A. B. Siegelaub, and C. C. Seltzer. Cigarette smoking and serum chemistry tests.J. Chron. Dis. 27:293–307 (1974).

    CAS  PubMed  Google Scholar 

  129. J. Lellough, D. Schwartz, M. H. Tran, and J. L. Beaumont. The relationships between smoking and levels of serum urea and uric acid, results of an epidemiological survey.J. Chron. Dis. 22:9–15 (1969).

    Google Scholar 

  130. J. K. Ma, P. P. Fu, and L. A. Luzzi. Protein binding of benzo[a]pyrene.J. Pharm. Sci. 66:209–213 (1977).

    CAS  PubMed  Google Scholar 

  131. V. G. Zannoni and M. M. Lynch. The role of ascorbic acid in drug metabolism.Drug Metab. Rev. 2:57–69 (1973).

    CAS  PubMed  Google Scholar 

  132. C. C. Seltzer. Constitution and heredity in relation to tobacco smoking.Ann. N.Y. Acad. Sci. 142:322–330 (1967).

    Google Scholar 

  133. M. Weitman, R. Scheble, K. G. Johnson, and H. Abbey. Correlations among use of drugs,Am. J. Public Health 62:156–160 (1972).

    Google Scholar 

  134. H. C. McKee, J. W. Rhoades, J. Campbell, and A. L. Gross. Acetonitrile in body fluids related to smoking.Public Health Rep. 77:553–554 (1962).

    CAS  PubMed Central  PubMed  Google Scholar 

  135. E. Maly. A simple test for exposure to polycyclic hydrocarbons.Bull. Environ. Contam. Toxicol. 6:422–425 (1971).

    CAS  PubMed  Google Scholar 

  136. S. G. Hundley and R. I. Freudenthal. High pressure liquid chromatography analysis of benzo[a]pyrene metabolism by microsomal enzymes from rhesus liver and lung.Cancer Res. 37:244–249 (1977).

    CAS  PubMed  Google Scholar 

  137. Anonymous. Marijuana.Med. Lett. Drugs Therapeutics 18:69–70 (1976).

    Google Scholar 

  138. W. D. M. Paton. Pharmacology of marijuana.Ann. Rev. Pharmacol. 15:191–220 (1975).

    CAS  PubMed  Google Scholar 

  139. W. D. M. Paton and R. G. Pertwee. Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism.Br. J. Pharmacol. 44:250–261 (1972).

    CAS  PubMed Central  PubMed  Google Scholar 

  140. G. Mitra, M. K. Poddar, and J. J. Ghosh.In vivo andin vitro effects of Δ9-tetrahydro-cannabinol on rat liver microsomal drug-metabolizing enzymes.Toxicol. Appl. Pharmacol. 35:523–530 (1976).

    CAS  PubMed  Google Scholar 

  141. A. J. Siemens, H. Kalant, J. M. Khanna, J. Marshman, and G. Ho. Effect of cannabis on pentobarbital-induced sleeping time and pentobarbital metabolism in the rat.Biochem. Pharmacol. 23:477–488 (1974).

    CAS  PubMed  Google Scholar 

  142. R. D. Sofia and H. Barry. Interactions of chronic and acute Δ1-tetrahydrocannabinol pretreatment with zoxazolamine and barbiturates.Res. Commun. Chem. Pathol. Pharmacol. 5:91–98 (1973).

    CAS  PubMed  Google Scholar 

  143. M. L. Herman and J. F. Bochantin. Effect of delta-9-tetrahydrocannabinol (marijuana) on liver microsomal dechlorinase activity: A preliminary report.Anesth. Analg. 51:929–932 (1972).

    Google Scholar 

  144. J. Marcotte, F. S. Skelton, M. G. Coté, and H. Witschi. Induction of aryl hydrocarbon hydroxylase in rat lung by marijuana smoke.Toxicol. Appl. Pharmacol. 33:231–245 (1975).

    CAS  PubMed  Google Scholar 

  145. E. S. Vesell and G. T. Passananti. Inhibition of drug metabolism in man.Drug Metab. Dispos. 1:402–410 (1973).

    CAS  PubMed  Google Scholar 

  146. W. S. Dalton, R. Martz, B. E. Rodda, L. Lemberger, and R. B. Forney. Influence of cannabidiol on secobarbital effects and plasma kinetics.Clin. Pharmacol. Ther. 20:695–700 (1976).

    CAS  PubMed  Google Scholar 

  147. L. Lemberger, N. R. Tamarken, J. Axelrod, and I. J. Kopin. Delta-9-tetrahydro-cannabinol: Metabolism and disposition in long-term marijuana smokers.Science 173:72–73 (1971).

    CAS  PubMed  Google Scholar 

  148. W. J. Jusko, J. S. Schentag, J. H. Clark, M. Gardner, and A. M. Yurchak. Enhanced biotransformation of theophylline in marijuana and tobacco smokers.Am. Rev. Resp. Dis. 117 (1978), in press.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, 14260, Amherst, New York

    William J. Jusko

Authors
  1. William J. Jusko
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported in part by Grant 1079 from the Council for Tobacco Research and Grant 20852 from the National Institutes of General Medical Sciences, NIH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jusko, W.J. Role of tobacco smoking in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 6, 7–39 (1978). https://doi.org/10.1007/BF01066061

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01066061

Key words

Search

Navigation